Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Cholesterol Screening/ Cholesterol Testing Services Market
The global Cholesterol Screening/Cholesterol Testing Services market was valued at USD 2,000,000 Million in 2025 and is projected to remain at USD 2,000,000 Million by 2035, reflecting a compound annual growth rate (CAGR) of 6.2% over the forecast period.
Market size
Growth trajectory through 2035
Cholesterol Screening/ Cholesterol Testing Services Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
2026-03
- 2026-03-13: New recommendations for advanced cholesterol testing methods were highlighted in public health communications, emphasizing their role in cardiovascular disease prevention.
Emerging opportunities added
- Technological advancements in testing methods Innovations such as point-of-care devices and home testing kits are expected to improve accessibility and convenience, broadening the customer base for cholesterol testing services.
- Integration with digital health platforms Opportunities exist to embed cholesterol screening within broader digital health ecosystems, enabling continuous monitoring and data-driven insights for both patients and providers.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $2,000.00 Bn
- CAGR
- 6.20%
- Expansion
- 1.8×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top-5 concentration
- Low · ~35%
Forces at play
▲ top tailwind
- ▼ headwind
- Cost and reimbursement challenges
- Named players
- 22 profiled
- Growth peak
- 2027–2031
Latest development
2026-03-13: New recommendations for advanced cholesterol testing methods were highlighted in public health communications, emphasizing their role in cardiovascular disease prevention
Report scope
What this report answers
The specific decisions and questions covered in the 125-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Cholesterol Screening/ Cholesterol Testing Services Market today ($2,000.00 Bn base), and how fast will it grow at 6.2% CAGR through 2035?
- Which of Lipid profile tests, Point-of-care cholesterol testing, Home-based cholesterol testing kits and other tracked segments holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Cardiovascular disease risk assessment, Preventive health screenings, Diabetes management applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics and 19 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising prevalence of cardiovascular diseases) and top restraints (led by Cost and reimbursement challenges), with quantified CAGR impact?
- What regulatory shifts and 1 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising prevalence of cardiovascular diseases The increasing global incidence of cardiovascular conditions is expected to drive demand for cholesterol testing services as part of preventive and diagnostic healthcare measures.
- Aging population Demographic trends toward an older global population are associated with higher risk profiles for elevated cholesterol, thereby increasing the need for regular screening and monitoring.
- Government health initiatives Public health campaigns and policy measures promoting cardiovascular health and routine cholesterol screenings are anticipated to support market expansion.
Restraints
Holding it back
- Cost and reimbursement challenges Financial barriers related to testing costs and insurance coverage limitations may constrain market growth, particularly in lower-income regions.
- Regulatory and compliance hurdles Stringent regulatory requirements for cholesterol testing devices and services can slow market entry and innovation, limiting scalability.
- Awareness and access disparities Uneven distribution of healthcare infrastructure and limited public awareness in certain geographies may impede widespread adoption of cholesterol testing services.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of cardiovascular diseases | +2.8% | Global | 2025–2035 |
| Aging population | +1.7% | Global | 2025–2035 |
| Government health initiatives | +1.4% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Cost and reimbursement challenges | −1.1% | Global | 2025–2029 |
| Regulatory and compliance hurdles | −0.7% | Global | 2025–2029 |
| Awareness and access disparities | −0.6% | Global | 2025–2029 |
Total 15 Lipid profile te 33% Point-of-care ch 27% Home-based chole 20% Advanced lipid t 13% Specialty lipid 7% Segmentation within the cholesterol testing services market is primarily defined by customer type and service delivery models.
Revenue share by type · 2025 base year
% OF $2,000.00 BN CHOLESTEROL SCREENING/ CHOLESTEROL TESTING SERVICES MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $2,000.00 Bn Cholesterol Screening/ Cholesterol Testing Services Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Lipid profile tests
-
Point-of-care cholesterol testing
-
Home-based cholesterol testing kits
-
Advanced lipid testing (e.g
-
LDL particle size analysis
-
Specialty lipid panels
By application
-
Cardiovascular disease risk assessment
-
Preventive health screenings
-
Diabetes management
-
Metabolic syndrome evaluation
-
Pediatric cholesterol screening (per new guidelines
-
Post-treatment monitoring for lipid-lowering therapies
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $2,000.00 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~42.0% in 2025. The region is expected to maintain a significant share of the market, supported by advanced healthcare infrastructure and high health awareness levels
Per-region detail
-
North America
The region is expected to maintain a significant share of the market, supported by advanced healthcare infrastructure and high health awareness levels
-
Europe
Market growth is driven by strong regulatory frameworks and government-led health campaigns promoting cardiovascular screening
-
Asia-Pacific
Rapidly expanding healthcare access and rising incidence of lifestyle-related diseases are anticipated to fuel market growth
-
Latin America
Growth is constrained by economic disparities and uneven healthcare distribution, though increasing health initiatives may gradually improve access
-
Middle East & Africa
Market potential is tempered by limited healthcare resources and lower health awareness, though targeted initiatives could unlock incremental demand
Competitive landscape
Who's competing, and how
The market is Low concentration. 22 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The market features a mix of multinational pharmaceutical companies and specialized diagnostic providers, with a moderate level of concentration among leading players.
Concentration snapshot
Top 5 players control 35.0% of the market
Aggregate 2025 share of the top 5 named players (real market share data). Individual company shares in the full report.
Competitive tiers
Players are bucketed by base-year market share: Leaders ≥ 7%, Challengers 3–7%, Emerging < 3%. Full tier rationale + revenue estimates in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Johnson & Johnson · Merck · Novartis
Tier 2 · Challengers
4companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Roche · AbbVie · Eli Lilly · AstraZeneca
Tier 3 · Emerging
15companies
Niche or early-stage, differentiated technology or early-mover positioning.
Thermo Fisher Scientific · Danaher Corporation · Roche Diagnostics · Abbott Diagnostics · Siemens Healthineers
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Thermo Fisher Scientific
Rank 01Share est. ~13%Revenue $■■■MHQ ■■■ -
Danaher Corporation
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Diagnostics
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Diagnostics
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Bio-Rad Laboratories
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
QIAGEN N.V
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Hologic Inc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 14 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
What is the worth of cholesterol screening/ cholesterol testing services market?
The cholesterol screening/ cholesterol testing services market is expected to grow at 7.9% CAGR from 2023 to 2030. It is expected to reach above USD 33.15 Billion by 2030 from USD 19.47 Billion in 2023. -
What is the size of the North America the cholesterol screening/ cholesterol testing services market?
North America held more than 41% of the cholesterol screening/ cholesterol testing services market revenue share in 2022 and will witness expansion in the forecast period. -
What are some of the market's driving forces?
The primary driver accelerating the growth of the market for cholesterol testing is the decline in physical activity. Additionally, the market is being driven by the need for better cholesterol management and routine check-ups and screenings. The market for over-the-counter cholesterol test kits is also anticipated to increase as a result of rising electronics miniaturization, which is also projected to play a beneficial role in the creation of self-testing kits. -
Which are the top companies to hold the market share in cholesterol screening/ cholesterol testing services market?
The cholesterol screening/ cholesterol testing services market key players include ACM Medical Laboratory, Clinical Reference Laboratory, Inc., Laboratory Corporation of America Holdings, Eurofins Scientific, Quest Diagnostics Incorporated, SYNLAB International GmbH, Fresenius Medical Care Holdings, Inc., Spectra Laboratories Inc., Unilabs, Bio-Reference Laboratories Inc. -
What is the leading application of cholesterol screening/ cholesterol testing services market?
Cholesterol screening/ cholesterol testing services market has leading application in diagnostic centers industry. -
Which is the largest regional market for cholesterol screening/ cholesterol testing services market?
In terms of market share and revenue, North America now rules the cholesterol testing market and will maintain this dominance during the projection period. This is a result of an increase in the number of elderly people, which has led to an increase in the number of cholesterol patients in this area. The focus will likely shift to clinical diagnostics, particularly cholesterol tests, in order to limit the bad events brought on by diseases like stroke, diabetes, and cardiovascular disease.
The Cholesterol Screening/ Cholesterol Testing Services Market is projected to reach $3,649.85 Bn by 2035, up from $2,000.00 Bn in 2025 — a 6.20% CAGR equating to roughly 1.8× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.